Related Experiment Video

Updated: Jan 3, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic

Koichiro Matsumura1, Tetsuro Sugiura2

  • 1Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan. kmatsumura1980@yahoo.co.jp.

Cardiovascular Ultrasound
|November 15, 2019
PubMed

Insights

Sodium glucose cotransporter 2 (SGLT2) inhibitors show cardiovascular benefits in type 2 diabetes mellitus patients. This review explores the mechanisms behind these improved cardiac outcomes, focusing on SGLT2 inhibitors

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is linked to high rates of left ventricular diastolic dysfunction and cardiovascular events.
  • Sodium glucose cotransporter 2 (SGLT2) inhibitors offer cardiovascular benefits beyond glucose lowering in type 2 diabetes mellitus (T2DM).
  • The precise mechanisms underlying these cardiovascular improvements remain unclear.

Purpose of the Study:

  • To review and discuss the likely mechanisms by which SGLT2 inhibitors improve cardiovascular outcomes.
  • To synthesize findings from experimental and clinical studies on cardiac function related to SGLT2 inhibitors.

Main Methods:

  • Literature review of experimental and clinical studies.
  • Analysis of studies focusing on cardiac function and SGLT2 inhibitor mechanisms.
  • Synthesis of evidence regarding cardiovascular outcomes.

Main Results:

  • SGLT2 inhibitors impact various pathways, including cardiac metabolism, inflammation, and fibrosis.
  • Evidence suggests direct beneficial effects on myocardial function and structure.
  • These effects may contribute to reduced cardiovascular events observed in clinical trials.

Conclusions:

  • SGLT2 inhibitors possess multifaceted mechanisms that favorably impact cardiovascular outcomes in T2DM.
  • Understanding these mechanisms is crucial for optimizing cardiovascular risk management in diabetic patients.
  • Further research is warranted to fully elucidate the cardioprotective effects of SGLT2 inhibitors.
Keywords:
Cardiac functionDiabetes mellitusSGLT2 inhibitor

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.0K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.3K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
857
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K